ArticleThe Journal of dermatology2026
Venetoclax-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE): Implications for Diagnosis and Treatment Continuation.
Article in The Journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is an uncommon type of cutaneous drug eruption, most frequently associated with antibiotics such as amoxicillin. Reports of SDRIFE induced by anticancer agents remain limited. We describe a case of SDRIFE in a 77-year-old man treated with venetoclax for acute myeloid leukemia. The eruption developed shortly after drug initiation and resolved rapidly following drug withdrawal without systemic involvement. Notably, venetoclax was continued for a certain period after onset without progression of symptoms. This case highlights the importance of recognizing SDRIFE in patients receiving chemotherapy and suggests that continuation of the causative agent may be feasible in selected cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.